Last week Adalta (1AD: $0.175) provided details of the successful completion of its Phase Ia trial with its lead antibody drug candidate, AD-214. The company will now move into two additional Phase I studies, one in healthy volunteers and the second in patients with fibrotic lung diseases.

Adalta’s (1AD) competitive prospects improved recently when a high profile drug, ziritaxestat, being developed by Galapagos and Gilead Sciences for idiopathic pulmonary fibrosis (IPF), was discontinued.